The United States DNA polymerase market is projected to reach USD 246.9 million by 2035, supported by rising investments in ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

A research team led by professor Olivia Merkel, Chair of Drug Delivery at LMU and co-spokesperson of the Cluster for Nucleic ...

Abstract: The CRISPR/Cas-based genome editing system has provided a powerful tool for control of gene activity within cells. Here, we model an experimentally plausible architecture harnessing the ...

Late-breaking data at the ESC Congress showcased the success of STX-1200, a novel CasXE-based therapy for durably lowering Lp(a). STX-1200 achieved unprecedented potency and specificity, with >90% ...

Department of Botany, Faculty of Science, Dayalbagh Educational Institute, Agra, Uttar Pradesh, India Recent breakthroughs in CRISPR/Cas genome editing have transformed molecular biology research and ...

Company will highlight the potential for Scribe’s X-Editor (XE) technology to address muscular dystrophies such as Duchenne Muscular Dystrophy Joint presentation with Prevail Therapeutics, a part of ...

1 Kiev College, Qilu University of Technology (Shandong Academy of Sciences), Jinan, China. 2 School of Food Science and Engineering, Qilu University of Technology (Shandong Academy of Sciences), ...